Clinical trials: Carboplatin, open to volunteers
Esophageal Cancer
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups.
- Trial name
- NCT07733830
- Testing
- Adebrelimab, Nab paclitaxel, Carboplatin
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Triple Negative Breast Cancer (TNBC)
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
- Conditions
- Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
- Trial name
- NCT06768931
- Testing
- Biolosion (oral probiotic compound preparation)
- Where
- 5 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Extensive-stage Small-cell Lung Cancer
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with…
- Trial name
- NCT07502300
- Testing
- BL-B01D1, Tislelizumab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 562 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
TNBC - Triple-Negative Breast Cancer
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for…
- Trial name
- NCT07256964
- Testing
- Toripalimab, PCb-EC, PCb
- Volunteers
- 216 people
- Sponsor
- Henan Cancer Hospital
Metastatic Cervical Cancer, Persistent Cervical Cancer
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical…
- Conditions
- Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer
- Trial name
- NCT07472153
- Testing
- PD-1 antibody, PD-L1 antibody, Chemotherapy and bevacizumab (CT-BEV)
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Advanced Solid Tumors
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy…
- Trial name
- NCT06741644
- Testing
- CS2009, Pemetrexed, Carboplatin
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 800 people
- Sponsor
- CStone Pharmaceuticals
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Cancer TNM Staging Regional Lymph Nodes (N)
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread
The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to…
- Trial name
- ONCOCOL01 (NCT03534713)
- Testing
- Carboplatin, Paclitaxel, Cisplatin
- Where
- 11 sites in France
- Volunteers
- 310 people
- Sponsor
- University Hospital, Toulouse
SCLC, Extensive Stage
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients.
- Trial name
- NCT06620796
- Testing
- Arm 1, second-line group
- Volunteers
- 70 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Carcinoma, Non-Small-Cell Lung
IMPT Dose Escalation for NSCLC (HyDose)
The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy.
- Trial name
- HyDose (NCT06484491)
- Testing
- Dose-escalated intensity-modulated proton therapy (IMPT-74), Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy, Immunotherapy: adjuvant durvalumab
- Where
- Netherlands
- Volunteers
- 87 people
- Sponsor
- University Medical Center Groningen
Ovarian Cancer, Fallopian Tube Cancer
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
- Trial name
- N-Plus (NCT05460000)
- Testing
- 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 640 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Relapsed or Metastatic Thymic Cancer, First-line Treatment
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
This study is a prospective, single arm phase II clinical trial ,aimed at exploring the efficacy and safety of the combination therapy of anti-PD-1 and VEGF bispecific antibody Ivonescimab combined with chemotherapy as first-line…
- Trial name
- iTHYM (NCT06750952)
- Testing
- Ivonescimab Combined With Chemotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Stage IIIA Non-small Cell Lung Cancer
Pathological Response After Neoadjuvant Treatment on NSCLC
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical…
- Trial name
- PLANET (NCT05167487)
- Testing
- Cisplatin, Carboplatin
- Where
- 17 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación GECP
Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in…
- Trial name
- NCT06008106
- Testing
- tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc
Endometrial Cancer Stage I, Endometrial Cancer Stage II
PROfiling Based Endometrial Cancer Adjuvant Therapy
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic…
- Trial name
- PROBEAT (NCT05179447)
- Testing
- Vaginal brachytherapy, External beam radiotherapy, Observation
- Where
- 10 sites in China
- Volunteers
- 590 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Non-Small Cell Lung Cancer
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases.
- Trial name
- NCT07756645
- Testing
- ABBV-1480, Pembrolizumab, Carboplatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 940 people
- Sponsor
- AbbVie
Endometrial Cancer, Uterine Neoplasms
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with…
- Trial name
- NSMP-ORANGE (NCT07831902)
- Testing
- medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel
- Where
- 12 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
Gastric-type Endocervical Adenocarcinoma, Cervical Cancer
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Background: Gastric-type endocervical adenocarcinoma (G-EAC) is a new classification of cervical mucinous carcinoma. G-EAC is a unique human papillomavirus unrelated adenocarcinoma that can be distinguished from typical…
- Trial name
- NCT06870565
- Testing
- paclitaxel and platinum, platinum
- Volunteers
- 238 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Triple Negative Breast Cancer (TNBC)
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with limited treatment options. Research suggests that using High-Intensity Focused Ultrasound (HIFU) to destroy the tumor and/or PD-1…
- Trial name
- NCT07394387
- Testing
- Sintilimab, Abraxane, Carboplatin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.